Table IV.
Characteristics of the study population.
| No. | Age, years | Gender | Immunophenotype | Initial WBC, ×109/l | Day 8 PB blast/μl | Risk group | Mean minimum WBC/μl | Outcome | |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Day 1 | Day 8 | ||||||||
| 1 | 12 | M | B | 81 | 63 | HR | HR | 1,167 | RFS |
| 2 | 11 | F | B | 581 | 632 | HR | HR | 450 | Relapsed |
| 3 | 14 | M | T | 279 | 14 | HR | HR | 433 | RFS |
| 4 | 8 | F | B | 7.2 | 7,684 | IR | HR | 367 | RFS |
| 5 | 9 | M | T | 430 | 116 | HR | HR | 500 | Relapsed |
| 6 | 12 | F | B | 8.2 | 1,269 | IR | HR | 733 | Relapsed |
| 7 | 14 | M | T | 1.5 | 0 | HR | HR | 367 | RFS |
| 8 | 7 | M | T | 259 | 20 | HR | HR | 433 | Relapsed |
| 9 | 12 | F | T | 147 | 247 | HR | HR | 233 | RFS |
| 10 | 15 | M | T | 42 | 0 | HR | HR | 433 | RFS |
| 11 | 6 | F | T | 11 | 0 | HR | HR | 233 | RFS |
| 12a | 3 | F | B | 8.5 | 825 | SR | SR | 667 | RFS |
| 13 | 7 | F | B | 12 | 76 | HR | HR | 300 | RFS |
| 14 | 11 | F | B | 21 | 12,802 | IR | HR | 200 | RFS |
| 15 | 13 | M | T | 126 | bND | HR | HR | 633 | Relapsed |
| 16 | 10 | M | B | 539 | 7 | HR | HR | 467 | RFS |
| 17 | 13 | M | B | 53 | 81 | HR | HR | 200 | RFS |
| 18 | 6 | M | T | 28 | 28 | HR | HR | 467 | RFS |
| 19 | 6 | M | T | 65 | 459 | HR | HR | 300 | RFS |
| Median | 11 | 52.9 | 69.5 | 433 | |||||
| IQR | 6–13 | 8.5–278.6 | 7–825 | 233–633 | |||||
Patient number 12 started treatment with the TCCSG L04-16 SR protocol. Hematological remission was achieved following remission induction, but leukemic infiltration remained in the liver and frontal bone. The patient was finally stratified into high-risk group and received all courses of the ALL-BFM 95 HR protocol with the exception of the induction phase.
Unable to determine ‘day eight’ since prednisolone monotherapy was transiently terminated due to tumor lysis syndrome.
The peripheral blood count decreased rapidly to <1,000/μl following initiation of prednisolone. WBC, white blood cell count; PB, peripheral blood; SR, standard-risk; IR, intermediate-risk; HR, high-risk; RFS, relapse-free survival; IQR, interquartile range; ND, no data.